Why Illumina Rallied 36.6% in December

07:05am, Tuesday, 09'th Jan 2024
The beaten-down stock got a couple of analyst upgrades. Illumina also confirmed it would sell Grail, its controversial 2021 acquisition.
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.
'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.
The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.
Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.
SAN DIEGO , Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan Healthcare Co
The saga over DNA sequencing firm Illumina Inc.'s (ILMN) controversial purchase of cancer diagnostic test maker GRAIL appears to be over.

Illumina Stock Rises After Sale of Grail

11:04am, Monday, 18'th Dec 2023
After over two years of antitrust battles, Illumina Inc (NASDAQ:ILMN) will sell its cancer diagnostic test maker Grail through a third-party sale of capital markets transaction by the second quarter n
Here's our daily look at three charts connected to recent news-driven price moves, with key technical levels to monitor.
Illumina Inc (NASDAQ:ILMN) stock traded on the front foot, up 5.6% to $134.25, after the company told investors it will seek a sale of its gene sequencing business Grail. It comes after European antit
The decision shows the company didn't see a way to overcome regulators' objections.

Illumina to divest cancer test maker Grail

04:29pm, Sunday, 17'th Dec 2023
The divestiture will be executed through a third-party sale or capital markets transaction, San Diego-based Illumina said in a statement, adding that it would finalize the terms by second quarter of 2
Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,
Judges also fault agency for not properly considering Illumina's plan to fix drawbacks.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE